Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of oral azacitidine for acute myeloid leukaemia that has completely disappeared after chemotherapy
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at oral azacitidine alongside best supportive care for acute myeloid leukaemia that has completely disappeared after treatment.
More about this trial
Doctors usually treat acute myeloid leukaemia (AML) with chemotherapy. The aim of treatment is to get your leukaemia into
When you are in complete remission, your doctor will monitor you closely and you have regular tests. You may also have
But there is a risk that your leukaemia will come back. This is called a recurrence. Researchers are looking for new treatments to reduce this risk, or at least extend the time before leukaemia comes back. In this trial they are looking at a drug called azacitidine. Doctors can already use azacitidine given into the bloodstream to treat AML in people who can’t have intensive chemotherapy.
The aims of the trial are to
- See if people having azacitidine tablets and best supportive care live longer than people who have best supportive care alone after treatment for AML
- Find out if azacitidine delays the recurrence of AML
- Learn more about the side effects and how azacitidine affects
quality of life
Who can enter
You may be able to enter this trial if you
- Have been diagnosed with acute myeloid leukaemia
- Have had chemotherapy and tests done in the last 3 months confirm that your leukaemia has completely disappeared
- Are at least 55 years old
- Are well enough to be up and about for at least some of each day, even if you need help looking after yourself (performance status 0, 1, 2 or 3)
- Have satisfactory blood test results
- Are willing to use 2 reliable contraception methods during the trial and for at least 3 months afterwards if there is any chance you or your partner could become pregnant
You cannot enter this trial if you
- Have a type of AML called acute promyelocytic leukaemia or FAB M3
- Have leukaemia that is linked to certain genetic changes (the trial team can advise you about this)
- Had azacitidine or a similar drug as part of the chemotherapy that got rid of your leukaemia
- Had azacitidine (or a similar drug) for a condition called MDS and then went on to develop acute myeloid leukaemia within 4 months of finishing this treatment
- Have leukaemia affecting your brain or spinal cord (your central nervous system)
- Have already had a bone marrow or stem cell transplant, or are due to have one
- Have had another experimental drug in the last 4 weeks
- Are known to be very sensitive to azacitidine or to a drug called mannitol
- Have an infection that can’t be controlled with medication
- Have certain heart problems (the trial team can advise you about this)
- Have any other medical condition or abnormal blood test results that could affect your taking part in the trial
- Can’t swallow tablets or have any problem with your
digestive systemthat means you wouldn’t be able to absorb tablets
- Have had any other cancer in the last year, unless it was a very early stage and has been successfully treated (the trial team can advise you about this)
- Are known to have HIV, hepatitis B or hepatitis C
- Are pregnant
This phase 3 trial will recruit 460 people in different countries. It is a randomised trial. The people taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in. And neither of you will know which group you are in. This is called a double blind trial.
Everybody taking part has
Half the people taking part will also have oral azacitidine. The other half will have a dummy drug (a
You usually have azacitidine as an injection just under your skin (subcutaneously). Occasionally you have it through a drip, or as an injection into a vein. But in this trial, the researchers are looking at a tablet form of azacitidine.
You take 2 azacitidine tablets (or dummy tablets) once a day for 2 weeks, followed by 2 weeks without any tablets. Each 4 week period is called a cycle of treatment.
As long as you don’t have bad side effects, you can carry on taking the tablets for as long as they are helping you, or until the end of the trial
The trial team will ask you to fill out two questionnaires before you start treatment, once a month during treatment and after you finish treatment. The questionnaires will ask about side effects and how you’ve been feeling. This is called a quality of life study.
The trial team will also give you a diary to keep at home. In this, you write down
- The time you take the trial tablets
- Whether you take any medicine to stop you feeling sick
- The number of tablets you take
You see the trial team and have some tests before you start treatment. The tests include
- Physical examination
- Blood tests
- Urine test
- Bone marrow test
- Heart trace (
- Chest X-ray
- Two pregnancy tests if you are female and could become pregnant
You go to hospital once a week for the first 8 weeks of treatment, then once every 2 weeks after that. You have regular blood tests. You have a bone marrow test every 3 months.
When you finish treatment, you see the trial team again about 4 weeks later. A member of the trial team will then contact you by phone to see how you are and whether you are having any treatment for AML. They will do this once a month for the 1st year and then once every 3 months after that.
The most common side effects of azacitidine include
- A drop in the number of blood cells causing an increased risk of infection, bleeding problems, tiredness and breathlessness
- Feeling or being sick
- High temperature (fever)
- Inflammation of the lining of your nose or throat
- Chest pain
- Rash or bruising
- Loss of appetite
- A risk of other cancers
The doctor will talk to you about all the possible side effects before you agree to take part in the trial.
How to join a clinical trial
Dr Mike Dennis
NIHR Clinical Research Network: Cancer